**REVIEW**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3282</td>
<td>Hepatitis B and circadian rhythm of the liver</td>
<td>Skrlec I, Talapko J</td>
</tr>
<tr>
<td>3314</td>
<td>Crosstalk between dietary patterns, obesity and nonalcoholic fatty liver disease</td>
<td>Ristic-Medic D, Bajerska J, Vucic V</td>
</tr>
</tbody>
</table>

**MINIREVIEWS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3346</td>
<td>Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy</td>
<td>Zhang CY, Liu S, Yang M</td>
</tr>
<tr>
<td>3359</td>
<td>Single-incision laparoscopic surgery to treat hepatopancreatobiliary cancer: A technical review</td>
<td>Chuang SH, Chuang SC</td>
</tr>
<tr>
<td>3383</td>
<td>Interventional strategies in infected necrotizing pancreatitis: Indications, timing, and outcomes</td>
<td>Purschke B, Bolm L, Meyer MN, Sato H</td>
</tr>
<tr>
<td>3398</td>
<td>Artificial intelligence in liver ultrasound</td>
<td>Cao LL, Peng M, Xie X, Chen GQ, Huang SY, Wang JY, Jiang F, Cui XW, Dietrich CF</td>
</tr>
<tr>
<td>3410</td>
<td>Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives</td>
<td>Ueno M, Takeda H, Takai A, Seno H</td>
</tr>
</tbody>
</table>

**ORIGINAL ARTICLE**

**Basic Study**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3422</td>
<td>Accumulation of poly (adenosine diphosphate-ribose) by sustained supply of calcium inducing mitochondrial stress in pancreatic cancer cells</td>
<td>Jeong KY, Sim JJ, Park M, Kim HM</td>
</tr>
</tbody>
</table>
## Contents

### Weekly Volume 28 Number 27 July 21, 2022

**RING finger and WD repeat domain 3 regulates proliferation and metastasis through the Wnt/β-catenin signalling pathways in hepatocellular carcinoma**


**Associations of gut microbiota with dyslipidemia based on sex differences in subjects from Northwestern China**


### Retrospective Cohort Study

**Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: A propensity matched retrospective cohort study**

Zhao Z, Yin XN, Wang J, Chen X, Cai ZL, Zhang B

### Retrospective Study

**Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis**


**Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China**

Liao MJ, Li J, Dang W, Chen DB, Qin WY, Chen P, Zhao BG, Ren LY, Xu TF, Chen HS, Liao WJ

### SYSTEMATIC REVIEWS

**Percutaneous transhepatic cholangiography vs endoscopic ultrasound-guided biliary drainage: A systematic review**

Hassan Z, Gadour E

### CASE REPORT

**Isolated gastric variceal bleeding related to non-cirrhotic portal hypertension following oxaliplatin-based chemotherapy: A case report**

Zhang X, Gao YY, Song DZ, Qian BX

### LETTER TO THE EDITOR

**Hepatitis B core-related antigen: Are we near a treatment endpoint?**

Gupta T
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Govind K Makharia, MD, DM,DNB, Professor, Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. govindmakharia@aiims.edu

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Wen-Wen Qi; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.
Hepatitis B core-related antigen: Are we near a treatment endpoint?

Tarana Gupta

**Abstract**

Different serological and virological markers in chronic hepatitis B patients guide staging of viral infection, and initiation and response to therapy. Due to the persistence of intrahepatic covalently closed circular DNA (cccDNA) in the hepatocyte nucleus, hepatitis B is not curable. Even after undetectable hepatitis B virus DNA levels, the persistence of hepatitis B surface antigen and novel markers such as hepatitis B core-related antigen (HBcrAg) indicate the persistence of intrahepatic cccDNA. In this study, HBcrAg levels at baseline and after 24 and 48 wk of antiviral therapy predicted hepatitis B e antigen seroconversion. Due to the poor sensitivity of assays and detectable levels in HBsAg-negative patients, the long-term utility of HBcrAg needs future research.

**Key Words:** Hepatitis B core-related antigen; Chronic hepatitis B; Covalently closed circular DNA; Hepatitis B e antigen seroconversion; Hepatitis B virus DNA; Pregenomic RNA

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Gupta T. Hepatitis B core-related antigen: Are we near a treatment endpoint? *World J Gastroenterol* 2022; 28(27): 3532-3534

**URL:** https://www.wjgnet.com/1007-9327/full/v28/i27/3532.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v28.i27.3532
TO THE EDITOR

We read with interest the study titled, “Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B” by Chi et al[1] in the World Journal of Gastroenterology. Hepatitis B core-related antigen (HBcrAg) and hepatitis B virus (HBV) RNA are potential serological markers of chronic hepatitis B infection and activity. In the HBV life cycle, intrahepatic covalently closed circular DNA (cccDNA) is transcribed into five RNAs of which pregenomic RNA is a precursor to synthesis of the viral genome by reverse transcription and precore mRNA is precursor to proteins hepatitis B core antigen. Hepatitis B e antigen (HBeAg) and p22cr are collectively called HBcrAg due to their identical 149 amino acid sequences. In addition, viral sequences also integrate in the host genome and can express hepatitis B surface antigen (HBsAg). Therefore, HBsAg quantification may not be exactly reflective of intrahepatic cccDNA levels. On the other hand, only cccDNA can express the viral genome. In real world settings, liver biopsy is not feasible for cccDNA quantification and a surrogate marker is needed in serum for intrahepatic cccDNA quantification. HBcrAg-related proteins can be detected in Dane particles, HBV DNA-negative Dane particles, and possibly in HBV RNA-containing virions[2]. Interestingly, nucleotide analogues (NAs) inhibit DNA polymerase and viral replication; they do not affect production of viral intermediate proteins such as HBcrAg. Therefore, even on antiviral treatment, HBcrAg can reflect cccDNA quantity and activity in hepatocytes.

This study determined the predictive role of HBcrAg for HBeAg seroconversion in chronic hepatitis B (CHB) patients. All patients were analyzed for HBcrAg, HBV RNA, and HBV DNA levels in blood and cccDNA quantification in liver biopsy specimen. Although there is treatment heterogeneity with two different cohorts of entecavir (n = 109) and pegylated-interferon (PEG-IFN) (n = 30) therapy, the authors found baseline HBcrAg levels correlating with cccDNA levels in patients with and without HBeAg seroconversion. However, the PEG-IFN group only had 30 patients, and as IFNs are immunomodulators that increase innate immune response in controlling HBV infection with higher HBeAg seroconversion rates compared to NA therapy, it may be premature to conclude that it only affects viral replication and not the production of other viral proteins. Therefore, some bias may be related to treatment heterogeneity.

This study also highlights that serum qHBcrAg levels at 24 and 48 wk of treatment better predict HBeAg seroconversion than qHBcrAg levels at baseline. Song et al[3] showed baseline HBcrAg levels < 4.9 log U/mL, > 2 log reduction of HBcrAg at week 28 having a positive predictive value 74% and 76%, and negative predictive value of 96% and 94%, respectively, for the prediction of spontaneous HBeAg seroconversion. In HBeAg-positive CHB patients, HBcrAg is high in the immune tolerant phase and negative predictive value of 96% and 94%, respectively, for the prediction of spontaneous HBeAg seroconversion. However, the PEG-IFN group only had 30 patients, and as IFNs are immunomodulators that increase innate immune response in controlling HBV infection with higher HBeAg seroconversion rates compared to NA therapy, it may be premature to conclude that it only affects viral replication and not the production of other viral proteins. Therefore, some bias may be related to treatment heterogeneity.

This study also demonstrates that correlation coefficients of serum HBV DNA and HBcrAg with intrahepatic cccDNA are 0.7 and 0.64-0.7, respectively, which are similar; however, in patients on antiviral therapy with undetectable serum HBV DNA, HBcrAg is the preferred marker for estimating intrahepatic cccDNA levels. Tseng et al[6] recently showed risk stratification of development of cirrhosis, and its complications and liver-related mortality in CHB patients over a period of 15.9 years by baseline HBcrAg levels. Carey et al[7] showed that HBcrAg and HBV RNA predict clinical flares in HBeAg-negative CHB patients with suppressed HBV DNA levels on nucleotide analogue therapy. Together, HBcrAg is a promising novel serum marker but with many limitations. First, with current available assays, the lower limit of detection is 2 log U/mL, so more sensitive assays are needed. Second, one study found detectable serum HBcrAg in 40% patients with HBsAg seroclearance[8]. Finally, large-scale studies in different ethnic groups are needed to determine the predictive value of HBcrAg with certain cut-off values in clinical practice especially occult HBV reactivation, HBV flare after nucleotide analogue cessation, and risk of hepatocellular carcinoma development.

FOOTNOTES

Author contributions: Gupta T wrote and critically revised the manuscript.

Conflict-of-interest statement: The author has no conflicts of interest to declare.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: India
REFERENCES


